Recently, the Alzheimer’s Drug Discovery Foundation gave researchers a $3.5 million award for promising early detection Alzheimer’s tests. We speak to Olivier Danos, who is working with researchers on developing a non-invasive test that could detect MCI and early Alzheimer’s.
If you find our articles and interviews helpful, please consider becoming a supporting member of our community. Frustrated by the lack of an editorially independent source of information on brain health and Alzheimer’s disease, we decided to create Being Patient. We are a team of dedicated journalists covering the latest research on Alzheimer’s, bringing you access to the experts and elevating the patient perspective on what it’s like to live with dementia.
Please help support our mission.
Olivier Danos, PhD, is a Founder, Vice President of the Executive Board and Scientific Advisor of FIRALIS SA, the mother company of Amoneta Diagnostics. He is a pioneer in the field of gene therapy, and has dedicated his career to advancing the use of this technology to develop life-saving therapies for patients. He is currently Senior Vice President and Chief Scientific Officer at REGENXBIO and was previously Senior Vice President of Cell and Gene Therapy at Biogen. Over the past twenty years, he has held leadership roles in cell and gene therapy as Director of the Gene Therapy Consortium of the University College of London, at the Necker Hospital – Enfants Malades in Paris, as Chief Scientific Officer of Genethon and as Senior Director of Research at Somatix Therapy Corporation. He has held senior research positions in France at the Centre National de la Recherche Scientifique and at the Institut Pasteur. Olivier is the former President and a founding member of the European Society of Gene and Cell Therapy. Olivier received a Master’s in Genetics and Molecular Biology at University of Paris Orsay, and his Ph.D. at the Pasteur Institute and University of Paris Diderot.